SMARCA2 Inhibitors
SMARCA2 (also known as BRM) is one of the two mutually exclusive catalytic ATPase subunits of the SWI/SNF (BAF) chromatin remodeling complex, the other being SMARCA4 (BRG1). These complexes utilize the energy from ATP hydrolysis to reposition nucleosomes, thereby regulating chromatin accessibility and gene expression. SMARCA2 and SMARCA4 share high structural homology and exhibit redundant functions in many cellular contexts. However, in various cancers, SMARCA4 is frequently inactivated by mutations or deletions, making the survival of these tumor cells critically dependent on the remaining paralog, SMARCA2. This dependency represents a classic example of paralog-based synthetic lethality, where the loss of one member of a functionally redundant pair creates a unique vulnerability that can be exploited therapeutically. The primary disease association for SMARCA2 inhibitors is SMARCA4-deficient cancer, which includes a subset of non-small cell lung cancers (NSCLC), small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), and various undifferentiated sarcomas.
In these malignancies, SMARCA4 loss leads to altered chromatin landscapes, and SMARCA2 becomes the sole driver of SWI/SNF-mediated transcriptional programs necessary for cell proliferation. Consequently, targeting SMARCA2 in a SMARCA4-null background induces cell cycle arrest and apoptosis, while having minimal impact on normal cells that express both paralogs. This high degree of selectivity is the cornerstone of the SMARCA2-targeted therapeutic strategy. Current research progress has moved from basic validation to the development of potent and selective SMARCA2 inhibitors and degraders. Developing small-molecule inhibitors that selectively target SMARCA2 over SMARCA4 is challenging due to the high conservation of their ATPase and bromodomains. To address this, Proteolysis-Targeting Chimeras (PROTACs) have emerged as a highly effective modality.
SMARCA2-selective degraders, such as those developed by companies like Arvinas, Foghorn Therapeutics, and Roivant, have demonstrated robust preclinical activity, showing deep and sustained degradation of SMARCA2 and significant tumor growth inhibition in SMARCA4-mutant xenograft models. Some of these candidates have recently entered Phase I clinical trials. Inhibitors are generally classified into three categories: ATP-competitive inhibitors targeting the ATPase domain, allosteric inhibitors, and PROTAC-based degraders. PROTACs are particularly favored because they can achieve higher selectivity by exploiting subtle differences in the surface residues of the two paralogs during the formation of the ternary complex with E3 ligases. Challenges in this field include the potential for "hook effects" with PROTACs, the need for precise patient stratification based on SMARCA4 status, and the risk of resistance through SWI/SNF complex remodeling. Future directions involve exploring SMARCA2 inhibition in combination with other epigenetic modulators or DNA damaging agents to enhance therapeutic efficacy.
As clinical data emerges, SMARCA2 inhibitors represent a promising new frontier in the treatment of SWI/SNF-mutant malignancies.
